Garfield Lauren D, Dixon David, Nowotny Petra, Lotrich Francis E, Pollock Bruce G, Kristjansson Sean D, Doré Peter M, Lenze Eric J
Department of Psychiatry, Washington University School of Medicine, St. Louis, MO.
Department of Psychiatry, Washington University School of Medicine, St. Louis, MO.
Am J Geriatr Psychiatry. 2014 Oct;22(10):971-9. doi: 10.1016/j.jagp.2013.07.003. Epub 2013 Sep 8.
Antidepressant side effects are a significant public health issue, associated with poor adherence, premature treatment discontinuation, and, rarely, significant harm. Older adults assume the largest and most serious burden of medication side effects. We investigated the association between antidepressant side effects and genetic variation in the serotonin system in anxious, older adults participating in a randomized, placebo-controlled trial of the selective serotonin reuptake inhibitor (SSRI) escitalopram.
Adults (N = 177) aged ≥ 60 years were randomized to active treatment or placebo for 12 weeks. Side effects were assessed using the Udvalg fur Kliniske Undersøgelser side-effect rating scale. Genetic polymorphisms were putative functional variants in the promoters of the serotonin transporter and 1A and 2A receptors (5-HTTLPR [L/S + rs25531], HTR1A rs6295, HTR2A rs6311, respectively).
Four significant drug-placebo side-effect differences were found: increased duration of sleep, dry mouth, diarrhea, and diminished sexual desire. Analyses using putative high- versus low-transcription genotype groupings revealed six pharmacogenetic effects: greater dry mouth and decreased sexual desire for the low- and high-expressing serotonin transporter genotypes, respectively, and greater diarrhea with the 1A receptor low-transcription genotype. Diminished sexual desire was experienced significantly more by high-expressing genotypes in the serotonin transporter, 1A, or 2A receptors. There was not a significant relationship between drug concentration and side effects nor a mean difference in drug concentration between low- and high-expressing genotypes.
Genetic variation in the serotonin system may predict who develops common SSRI side effects and why. More work is needed to further characterize this genetic modulation and to translate research findings into strategies useful for more personalized patient care.
抗抑郁药的副作用是一个重大的公共卫生问题,与依从性差、过早停药以及罕见的严重危害相关。老年人承担着药物副作用最大且最严重的负担。我们在参与选择性5-羟色胺再摄取抑制剂(SSRI)艾司西酞普兰随机、安慰剂对照试验的焦虑老年人中,研究了抗抑郁药副作用与5-羟色胺系统基因变异之间的关联。
年龄≥60岁的成年人(N = 177)被随机分配接受12周的活性治疗或安慰剂治疗。使用乌普萨拉临床研究副作用评定量表评估副作用。基因多态性是5-羟色胺转运体、1A和2A受体启动子中的推定功能性变体(分别为5-HTTLPR [L/S + rs25531]、HTR1A rs6295、HTR2A rs6311)。
发现了四项显著的药物 - 安慰剂副作用差异:睡眠时间延长、口干、腹泻和性欲减退。使用推定的高转录与低转录基因型分组进行的分析揭示了六种药物遗传学效应:低表达和高表达5-羟色胺转运体基因型分别导致更严重的口干和性欲减退,以及1A受体低转录基因型导致更严重的腹泻。5-羟色胺转运体、1A或2A受体高表达基因型的个体性欲减退更为明显。药物浓度与副作用之间没有显著关系,低表达和高表达基因型之间的药物浓度也没有平均差异。
5-羟色胺系统的基因变异可能预测谁会出现常见的SSRI副作用以及原因。需要开展更多工作以进一步明确这种基因调节作用,并将研究结果转化为有助于更个性化患者护理的策略。